Clinical trials: Zoledronic acid, completed
Metastatic Cancer, Prostate Cancer
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.
- Trial name
- NCT00079001
- Testing
- zoledronic acid, androgen deprivation therapy, GnRH agonist
- Where
- 241 sites in United States, Canada
- Volunteers
- 645 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
The purpose of this study is to evaluate the effect of zoledronic acid and physical activity on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast cancer.
- Trial name
- NCT00202059
- Testing
- Zoledronic acid, Physical activity intervention
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- HealthPartners Institute
Hormone-Refractory Prostate Cancer
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
- Trial name
- NCT00151073
- Testing
- Zoledronic acid, Estramustine, Docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan Rogel Cancer Center
Osteoporosis
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk.
- Trial name
- NCT00100620
- Testing
- Zoledronic Acid
- Where
- 6 sites in United States
- Volunteers
- 802 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
This study will evaluate the effects of zoledronic acid 5 mg infusion on BMD and biochemical markers of bone in post-menopausal osteoporotic patients aged between 50-65.
- Trial name
- NCT00909961
- Testing
- Zoledronic acid
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer
- Trial name
- NCT00247650
- Testing
- Zoledronic Acid; Letrozole
- Where
- 10 sites in Canada
- Volunteers
- 190 people
- Sponsor
- Novartis
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fractures, Bone
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors.
- Trial name
- NCT01920568
- Testing
- Denosumab 70 mg/mL, Zoledronic acid 4 mg, Calcium supplement
- Where
- 25 sites in China, Singapore and 1 more
- Volunteers
- 487 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma and Plasma Cell Neoplasm, Pain
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells.
- Trial name
- NCT00482378
- Testing
- Pamidronate, Zoledronic acid, Sm 153 lexidronam
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Early-stage Breast Cancer
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
REaCT ZOL will compare one 4 mg dose of Zoledronate vs. one 4 mg dose of Zoledronate given every 6 months for 3 years.
- Trial name
- REaCT-ZOL (NCT03664687)
- Testing
- Zoledronate
- Where
- 6 sites in Canada
- Volunteers
- 211 people
- Sponsor
- Ottawa Hospital Research Institute
Bone Density, Pain
Bisphosphonate Therapy in MONA Spectrum Disorder
Multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder is a rare inherited progressive skeletal disorder caused by mutations in the matrix metalloproteinase 2 (MMP2) gene. Treatment options are limited.
- Conditions
- Bone Density, Pain, Fracture
- Trial name
- NCT02823925
- Testing
- Pamidronate or Zoledronate
- Volunteers
- 3 people
- Sponsor
- Medical University Innsbruck
Breast Cancer
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen.
- Trial name
- NCT00320710
- Testing
- Zoledronic acid
- Where
- 92 sites in United States
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
- Trial name
- NCT00213980
- Testing
- Zoledronate
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Wisconsin, Madison
Multiple Myeloma Bone Disease
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
This study has two portions, a phase I portion and a phase II portion. The purpose of the phase I portion is to assess the maximum-tolerated dose (MTD) and to characterize dose limiting toxicity (DLT) of escalating doses of…
- Trial name
- NCT00741377
- Testing
- BHQ880, Zoledronic acid
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Pain
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
- Trial name
- TRAPEZE (NCT00375648)
- Testing
- Zoledronic acid
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Progeria, Hutchinson-Gilford Syndrome
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
This is an open label single arm feasibility trial. A combination of two oral agents (pravastatin and lonafarnib) and one intravenous (IV) agent (zoledronic acid) will be administered at doses and schedule currently applied in…
- Trial name
- NCT00879034
- Testing
- Lonafarnib, Zoledronic Acid, Pravastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Children's Hospital
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Orthodontic Appliance Complication
Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews
Background: Orthodontic miniscrews are widely used as temporary anchorage devices; however, failure remains a clinical concern. Bisphosphonates may enhance bone stability, but evidence on their local application is limited.
- Trial name
- NCT07546058
- Testing
- Zoledronic Acid, Normal saline (0.9% sodium chloride)
- Where
- Syria
- Volunteers
- 68 people
- Sponsor
- Latakia University
Osteogenesis Imperfecta
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
- Trial name
- NCT00131118
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals